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Professor Mark Bower  
E-mail: m.bower@imperial.ac.uk 
 
 
Letter to the Editor. 
 
Dear Editor, 
 
In the combined anti-retroviral therapy (cART) era, non-small cell lung cancer 
(NSCLC) is a highly incident cause of morbidity and mortality in people living with HIV 
(PLHIV)[1]. The immune-pathogenesis of NSCLC and HIV infection both rely on 
programmed-death 1 (PD-1) receptor-ligand interaction as a mechanism to induce T-cell 
exhaustion. To date, PLHIV have been excluded from clinical trials of immune-
checkpoint inhibitors (ICPI), on the presumption that anti-tumour immunity might be 
compromised by HIV infection. To verify this, we evaluated the clinico-pathologic 
significance of PD-ligands expression in a consecutive series of 221 archival NSCLC 
samples, 24 of which were HIV-associated (Table S1).  
Most patients with HIV-associated NSCLC were active smokers (n=18, 75%; 
median 40 packs/year, IQR 48), established on cART (n=22, 92%) for a median 
duration of 9.7 years (IQR 7.1) with CD4 counts >250 cells/mm3 (n=19, 79%) and 
suppressed HIV RNA (n=20, 80%). Molecular profiling data (n=12/24) revealed two 
EGFR mutation carriers. Tissue-microarray sections underwent PD-L1, PD-L2 
immunostaining and multiplex immunohistochemistry (n=21) for PD-1, CD4, CD8 and 
CD68 (Figures 1A-D, Supplementary Materials). Prevalence of PD-L1 positivity was 
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45% in tumour (n=11/24) and 8% (n=2/24) in tumour-infiltrating cells, whereas tumoural 
PD-L2 positivity was found in 33% (n=8/24) (Figure S1). Following 2:1 case-control 
matching for age, gender, grade, stage and histotype (n=66), PD-L1 (12/23 vs 14/43, 
p=0.12) and PD-L2 expression (9/23 vs 25/45, p=0.20) were unrelated to the presence 
and severity of HIV-related immune dysfunction as indicated by nadir CD4 counts 
(p=1.0, p=0.8), HIV RNA levels (p=0.14, p=0.24), duration of HIV infection and cART 
(p>0.05) suggesting independence between anti-viral and anti-tumour immune-
tolerogenesis. In keeping with this view, we documented a positive correlation between 
PD-L1 expression and density of tumour-infiltrating (TIL) (Figure 1A-F) but not 
peripherally circulating lymphocytes (Figure 1G-H), highlighting polarization of the 
tumour microenviroment to a type-1 response[2]. In type-1 or PD-L1+/TIL+ tumours, TILs 
are chemo-attracted to malignant cells and turned off by PD-L1 engagement. Type-1 
tumours are generally sensitive to single-agent PD-1/PD-L1-targeted checkpoint 
blockade, due to the presence of an immune-reactive microenvironment[3].   
In an exploratory targeted transcriptomic analysis of 5 HIV-positive cases and 3 
stage/histotype-matched controls using the NanoString PanCancer-Immune panel 
(NanoString Technologies, Seattle, USA), we demonstrated enrichment of transcripts 
involved in chemotaxis (CCL18), antigen presentation (HLA-A, HLA-DRA), cytotoxic T-
cell (LAMP-1) and macrophage activation (SPP1, Figure 1I-L) in HIV-associated 
NSCLC, consistent with previous studies[4]. Whilst not exhaustive and limited by 
sample size, our findings challenge the conception that well-controlled HIV infection 
may negatively influence cancer-specific immune dysfunction by preliminarily 
demonstrating the presence of an immune-reactive microenvironment in HIV-associated 
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NSCLC (Figure S2-3, Table S2-3). This concept should be further explored by 
comparing normal and neoplastic lung tissues in prospective studies. 
  As accumulating evidence shows PD-1/PD-L1-targeted ICPI to be safe and 
capable of enhancing HIV-specific immunity[5] without unexpected toxicity, taken 
together, our data suggest that HIV-associated NSCLC may be equally reactive to ICPI. 
Whilst preliminary in nature and warranting validation in larger patient cohorts treated 
with ICPI, our study supports an immunobiologic rationale for the development of PD-
1/PD-L1-targeted ICPI in HIV-associated NSCLC.  
 
References. 
1. Bower M, Powles T, Nelson M et al. HIV-related lung cancer in the era of highly 
active antiretroviral therapy. AIDS 2003; 17: 371-375. 
2. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell 
Infiltration and PD-L1. Cancer Res 2015; 75: 2139-2145. 
3. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and 
other features of the tumor immune microenvironment with response to anti-PD-1 
therapy. Clin Cancer Res 2014; 20: 5064-5074. 
4. Domblides C, Antoine M, Hamard C et al. Non-small cell lung cancer from HIV-
infected patients expressed PD-L1 with marked inflammatory infiltrates. AIDS 2017. 
5. Guihot A, Marcelin AG, Massiani MA et al. Drastic decrease of the HIV reservoir 
in a patient treated with nivolumab for lung cancer. Ann Oncol 2017. 
Figure Legends. 
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Figure 1. Panel A-D. Representative sections of HIV-associated NSCLC co-
immunostained for CD8 (red chromogen), CD4 (brown chromogen), PD-1 (blue 
chromogen) and CD68 (green chromogen) illustrating CD4/CD8 enrichment in PD-L1-
positive HIV-associated NSCLC (Panels A-C) compared to PD-L1-negative 
counterparts (Panels B-D). Panels E-F Histograms of multiplex immunohistochemistry 
data illustrating the relationship between the CD4 and CD8-positive immune infiltrate 
expressed as number of immunopositive cells per high power field (HPF) according to 
tumour cell PD-L1 (Panel E) and PD-L2 expression status (Panel F) in HIV-associated 
NSCLC (n=21). Panels G-H Peripheral blood immunophenotyping illustrates the 
relationship between peripheral CD4, CD8, CD19 and CD56-positive cell counts 
categorized according to tumoural PD-L1 (Panel G) and PD-L2 expression status 
(Panel H) in HIV-associated NSCLC (n=24). Medians and interquartile ranges are 
reported. Panel I: Volcano plot of differentially-regulated genes identified by Nanostring 
analysis. The Benjamini-Hockberg p-values are correlated to fold-changes in transcripts 
identified in HIV-positive NSCLC (n=5) versus HIV-negative controls (n=3). Transcripts 
achieving statistical significance (FDR q-value of 5%) are highlighted by the presence of 
the corresponding gene name. Panel L. Heat map profile of the 12 transcripts that are 
differentially regulated in HIV-associated NSCLC compared to controls. Expression 
levels are shown as log transformed values of normalized counts (ln2).  
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Supplementary Materials and Methods. 
 
Functional immune characterization of HIV-associated non-small cell lung cancer. 
David J. Pinato et al. 
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Patient Samples. 
From a series of 256 patients diagnosed with NSCLC (2001-2016) within Imperial 
College London affiliated hospitals, we identified a subset of 36 patients with NSCLC on 
a background of HIV whose oncological and HIV care was coordinated within the 
National Centre for HIV malignancies at the Chelsea and Westminster Hospital. We 
excluded 36 patients due to insufficient tissue, leaving 221 available for analysis: 24 
HIV-positive and 197 HIV-negative. Clinico-pathologic variables including overall 
survival (OS) were derived from a prospectively maintained dataset. The study was 
approved by the Imperial College Tissue Bank (R16005), which issued a waiver of 
consent due to the retrospective nature of the study. Study related procedures were 
conducted in accordance to the Declaration of Helsinki. 
 
Patients and Tumour Characteristics. 
Our study population consisted of 234 patients, out of whom 218 (93%) had full 
immunohistochemical data for PD-L1 and PD-L2 expression, leaving a total of 24 HIV-
positive and 194 HIV-negative individuals. The clinico-pathologic features of our patient 
population are described in Table S1. Patients with HIV-associated NSCLC were 
predominantly of male gender (n=21, 87%). The most prevalent risk factor for HIV 
infection was MSM sexual transmission (n=15, 63%). The majority of patients (n=19, 
79%) had peripheral CD4 counts >250 cells/mm3 and a suppressed HIV viral load 
(n=20, 80%). Most patients were established on anti-retroviral therapy (ARVs) at the 
time of LC diagnosis (n=22, 92%) with a median duration of treatment of 9.7 years (IQR 
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7.1 years) and a median interval between diagnosis of HIV and NSCLC of 16 years 
(IQR 8.2 years). A total of 6 patients (25%) had a history of at least one previous 
respiratory opportunistic infection (OI) including recurrent bacterial (n=3), mycobacterial 
(n=3), fungal OIs (n=2) and Pneumocystis pneumonia (n=2).  According to the U.S. 
Centers for Disease Control and Prevention (CDC) classification system, the majority of 
patients satisfied group C criteria (n=14). Overall, 8 patients (33%) were treated 
radically for their NSCLC either by surgery (n=7, 29%) or radical radiotherapy (n=1, 
4%), whereas 14 (58%) received palliative treatments including chemotherapy (n=10, 
42%), targeted therapies (n=3, 12%) and palliative radiotherapy (n=8, 33%). Two 
patients (8%) received best supportive care only. At the time of censoring in June 2017, 
19 patients (80%) had died and the median overall survival (OS) was 9.5 months 
(95%CI 4.8-14.2). 
 
Tissue microarray (TMA) construction and immunohistochemistry (IHC). 
Following review of haematoxylin and eosin (H&E) slides to confirm salient 
histopathologic features including TNM stage (7th edition)1, one mm tissue cores from 
archival paraffin-embedded specimens were sampled in triplicate to prepare TMA blocks 
using an MTA-1 Manual Tissue Microarrayer (Beecher Instruments, USA)2. Biopsy 
samples lacking enough tissue for re-embedding in a TMA blocks were processed on 
full-face sections. 
IHC staining was performed on 5µm sections using the Leica Bond RX stainer (Leica, 
Buffalo, IL) using a pre-specified protocol3. The primary antibodies anti-PD-L1 (Clone 
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E1L3N; Cell Signalling Cat. Nr. 13684), anti-PD-L2 (Sigma Aldrich, Cat. Nr. 3500395) 
were incubated overnight at the concentration 1:100 and 1:300, respectively. A 
secondary antibody was incubated for 1 hour at room temperature and then processed 
using the Polymer-HRP Kit (BioGenex, San Ramon CA, US) with development in 
diaminobenzidine and Mayer’s Haematoxylin counterstaining. For each experiment, 
positive (de-identified tonsil) and negative controls (omission of primary antibody on 
tonsil sections) were processed in parallel. HIV-associated NSCLC samples (n=21) 
underwent multi-colour immune cell phenotyping for PD-1 (clone NAT 105/E3), CD4 
(Spring Biosciences, clone SP35), CD8 (clone SP239) and CD68 (clone SP251) based 
on a previously optimised protocol4. Specificity of immunostaining was confirmed by a 
haematopathologist with expertise in multiplex IHC (TM) and immune cell density was 
quantified on a total of 10 high-power fields (HPF) per sample. 
IHC expression of PD ligands was evaluated independently by 2 lung histopathologists 
(FAM, NG) using a semi-quantitative immuno-histoscore (IHS) derived by multiplying 
percentage of immunopositive cells by signal intensity2. Continuous IHS ranging from 0-
300 were categorised around the median of the distribution for clinicopathologic 
correlation. Tumour cell or peri-tumoural stromal expression was considered specific 
only if membranous or concomitant membranous and cytoplasmic staining were 
present.  
 
NanoString Immune profiling. 
We performed H&E-guided manual microdissection of target tumour tissue in a subset 
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of 10 samples (6 cases and 4 stage and histotype-matched controls) and extracted total 
RNA on 2-4 5 µM-thick tissue sections using the Qiagen RNAeasy FFPE kit (Qiagen, 
Venlo, NL, Cat Nr. 73504) according to the manufacturer’s instructions. We performed 
targeted transcriptomic profiling using the NanoString PanCancer Immune panel on an 
nCounter® Analysis System (NanoString Technologies, Seattle, USA). Hybridization 
reactions were performed according to the manufacturer's instructions. The PanCancer 
Immune CodeSet (NanoString Technologies) contains a biotinylated capture probe for 
770 target genes and 40 housekeeping genes. For each sample 200 ng of total RNA 
were hybridised to multi-colour-tagged reporter probes for 18 hours at 65°C and 
processed on an automated nCounter® Prep Station. Following purification and 
immobilisation of hybridized samples, target mRNA quantification was performed on an 
nCounter® Digital Analyzer, counting 600 fields of view per reaction. Quantified 
expression data were analyzed using the nSolver analysis software version 4.0. The 
resulting counts were normalized to the average counts for all control spikes in each 
sample and subsequently normalized using the geometric mean of the housekeeping 
genes. Samples flagged for high normalisation values or with quality control standards 
falling outside default settings were examined carefully and a total of 2 samples (1 HIV, 
1 control) were excluded, leaving 8 samples (5 HIV and 3 controls) for final analysis.  
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Statistical analysis. 
Patients’ characteristics were presented as means or medians as appropriate. Pearson 
chi-square or Fisher’s exact tests were used for analysis of proportions. All statistical 
analyses were performed using SPSS version 21.0 (IBM Inc., Chicago, IL, USA) and 
GraphPad PRISM (GraphPad software inc., La Jolla, CA, USA) with all estimates being 
reported with corresponding 95% confidence intervals and a two-tailed level of 
significance of p<0.05. Differential expression of genes of interest was determined using 
the false discovery rate method (FDR) of Benjamini and Hochberg, with pre-defined q-
value of 5%. 
 
Supplementary References. 
1. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 
7th Edition. Wiley-Blackwell, 2009. 
2. Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K, et al. An 
expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: 
correlation with tumour phenotype and survival outcomes. Br J Cancer 2014; 110:115-22. 
3. Pinato DJ, Shiner RJ, White SD, Black JR, Trivedi P, Stebbing J, et al. Intra-tumoral 
heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and 
metastatic lung cancer: Implications for immunotherapy. Oncoimmunology 2016; 5:e1213934. 
4. Marafioti T, Jones M, Facchetti F, Diss TC, Du MQ, Isaacson PG, et al. Phenotype and 
genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic 
morphology. Blood 2003; 102:2868-76. 
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Functional immune characterization of HIV-associated non-small cell lung cancer. 
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Figure S1. 
 
 
Panels A-B. Representative sections illustrating PD-L1 (A) and PD-L2 expression (B) in 
HIV-associated NSCLC. 
 
Panel C illustrates the relationship between PD-L1 and PD-L2 expression in HIV-
associated NSCLC. Panel D illustrates the difference in PD-L1 and PD-L2 expression 
across the various TNM stages of NSCLC in HIV-associated NSCLC (n=24). Medians 
and interquartile ranges are reported.  
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E 
 
 
 
 
F 
 
 
 
 
Panels E-F Histograms of multiplex immunohistochemistry experiments illustrating the 
relationship between PD-L1 (Panel E) and PD-L2 expression (Panel F) and the 
proportion of CD4, CD8, PD-1, CD68 or CD8/PD-1 and CD4/PD-1 immunopositive cells. 
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Figure S2. 
 
 
Scatter plot of the Nanostring transcriptomic analysis using the Nanostring PanCancer 
Immune panel. Each dot represents the average Log2 normalised read counts for each 
analysed transcript across two groups: HIV-associated NSCLC (n=5, blue) plotted 
against HIV-negative controls (n=3, black). The relative abundance of each transcript 
above (overexpression) or below the black line (underexpression) can be visually 
inferred to determine gene expression differences across cases versus controls. Gene 
expression was analysed using the Nsolver software (Version 4.0).  
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Figure S3. 
 
 
Heat map diagram of differential gene expression using Euclidean distance metrics in 
HIV-associated NSCLC compared to HIV-negative controls. Each column represents a 
patient and each row represents a single gene. Expression levels are coloured yellow 
for high intensities and green for low intensities. 
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Table S1.  
Clinicopathologic features of the patient cohort. 
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Abbreviations:  
CDC system: U.S. Centers for Disease Control and Prevention (CDC) classification 
system; ARV antiretrovirals, Protease Inhibitor (PI), Non-nuclease reverse transcriptase 
inhibitor (NNRTI), Integrase inhibitor (II), Nucleoside reverse transcriptase inhibitor 
(NRTI), MSM men who have sex with men. 
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Table S2.  
Clinico-pathologic characteristics of patient samples undergoing targeted transcriptomic 
profiling using the Nanostring PanCancer Immune Panel. 
 
Patient Histotype TNM Stage 
HIV 1 Squamous cell carcinoma I 
HIV 2 Squamous cell carcinoma I 
HIV 3 Squamous cell carcinoma II 
HIV 4 Adenocarcinoma II 
HIV 5 Pleomorphic carcinoma II 
Control 1 Squamous cell carcinoma I 
Control 2 Squamous cell carcinoma II 
Control 3 Adenocarcinoma II 
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Table S3.  
Differentially regulated transcripts in HIV-associated NSCLC compared to HIV-negative 
controls. 
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Professor Mark Bower  
E-mail: m.bower@imperial.ac.uk 
 
 
Letter to the Editor. 
 
Dear Editor, 
 
In the combined anti-retroviral therapy (cART) era, non-small cell lung cancer 
(NSCLC) is a highly incident cause of morbidity and mortality in people living with HIV 
(PLHIV)[1]. The immune-pathogenesis of NSCLC and HIV infection both rely on 
programmed-death 1 (PD-1) receptor-ligand interaction as a mechanism to induce T-cell 
exhaustion. To date, PLHIV have been excluded from clinical trials of immune-
checkpoint inhibitors (ICPI), on the presumption that anti-tumour immunity might be 
compromised by HIV infection. To verify this, we evaluated the clinico-pathologic 
significance of PD-ligands expression in a consecutive series of 221 archival NSCLC 
samples, 24 of which were HIV-associated (Table S1).  
Most patients with HIV-associated NSCLC were active smokers (n=18, 75%; 
median 40 packs/year, IQR 48), established on cART (n=22, 92%) for a median 
duration of 9.7 years (IQR 7.1) with CD4 counts >250 cells/mm3 (n=19, 79%) and 
suppressed HIV RNA (n=20, 80%). Molecular profiling data (n=12/24) revealed two 
EGFR mutation carriers. Tissue-microarray sections underwent PD-L1, PD-L2 
immunostaining and multiplex immunohistochemistry (n=21) for PD-1, CD4, CD8 and 
CD68 (Figures 1A-D, Supplementary Materials). Prevalence of PD-L1 positivity was 
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 3 
45% in tumour (n=11/24) and 8% (n=2/24) in tumour-infiltrating cells, whereas tumoural 
PD-L2 positivity was found in 33% (n=8/24) (Figure S1). Following 2:1 case-control 
matching for age, gender, grade, stage and histotype (n=66), PD-L1 (12/23 vs 14/43, 
p=0.12) and PD-L2 expression (9/23 vs 25/45, p=0.20) were unrelated to the presence 
and severity of HIV-related immune dysfunction as indicated by nadir CD4 counts 
(p=1.0, p=0.8), HIV RNA levels (p=0.14, p=0.24), duration of HIV infection and cART 
(p>0.05) suggesting independence between anti-viral and anti-tumour immune-
tolerogenesis. In keeping with this view, we documented a positive correlation between 
PD-L1 expression and density of tumour-infiltrating (TIL) (Figure 1A-F) but not 
peripherally circulating lymphocytes (Figure 1G-H), highlighting polarization of the 
tumour microenviroment to a type-1 response[2]. In type-1 or PD-L1+/TIL+ tumours, TILs 
are chemo-attracted to malignant cells and turned off by PD-L1 engagement. Type-1 
tumours are generally sensitive to single-agent PD-1/PD-L1-targeted checkpoint 
blockade, due to the presence of an immune-reactive microenvironment[3].   
In an exploratory targeted transcriptomic analysis of 5 HIV-positive cases and 3 
stage/histotype-matched controls using the NanoString PanCancer-Immune panel 
(NanoString Technologies, Seattle, USA), we demonstrated enrichment of transcripts 
involved in chemotaxis (CCL18), antigen presentation (HLA-A, HLA-DRA), cytotoxic T-
cell (LAMP-1) and macrophage activation (SPP1, Figure 1I-L) in HIV-associated 
NSCLC, consistent with previous studies[4]. Whilst not exhaustive and limited by 
sample size, our findings challenge the conception that well-controlled HIV infection 
may negatively influence cancer-specific immune dysfunction by preliminarily 
demonstrating the presence of an immune-reactive microenvironment in HIV-associated 
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NSCLC (Figure S2-3, Table S2-3). This concept should be further explored by 
comparing normal and neoplastic lung tissues in prospective studies. 
  As accumulating evidence shows PD-1/PD-L1-targeted ICPI to be safe and 
capable of enhancing HIV-specific immunity[5] without unexpected toxicity, taken 
together, our data suggest that HIV-associated NSCLC may be equally reactive to ICPI. 
Whilst preliminary in nature and warranting validation in larger patient cohorts treated 
with ICPI, our study supports an immunobiologic rationale for the development of PD-
1/PD-L1-targeted ICPI in HIV-associated NSCLC.  
 
References. 
1. Bower M, Powles T, Nelson M et al. HIV-related lung cancer in the era of highly 
active antiretroviral therapy. AIDS 2003; 17: 371-375. 
2. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell 
Infiltration and PD-L1. Cancer Res 2015; 75: 2139-2145. 
3. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and 
other features of the tumor immune microenvironment with response to anti-PD-1 
therapy. Clin Cancer Res 2014; 20: 5064-5074. 
4. Domblides C, Antoine M, Hamard C et al. Non-small cell lung cancer from HIV-
infected patients expressed PD-L1 with marked inflammatory infiltrates. AIDS 2017. 
5. Guihot A, Marcelin AG, Massiani MA et al. Drastic decrease of the HIV reservoir 
in a patient treated with nivolumab for lung cancer. Ann Oncol 2017. 
Figure Legends. 
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Figure 1. Panel A-D. Representative sections of HIV-associated NSCLC co-
immunostained for CD8 (red chromogen), CD4 (brown chromogen), PD-1 (blue 
chromogen) and CD68 (green chromogen) illustrating CD4/CD8 enrichment in PD-L1-
positive HIV-associated NSCLC (Panels A-C) compared to PD-L1-negative 
counterparts (Panels B-D). Panels E-F Histograms of multiplex immunohistochemistry 
data illustrating the relationship between the CD4 and CD8-positive immune infiltrate 
expressed as number of immunopositive cells per high power field (HPF) according to 
tumour cell PD-L1 (Panel E) and PD-L2 expression status (Panel F) in HIV-associated 
NSCLC (n=21). Panels G-H Peripheral blood immunophenotyping illustrates the 
relationship between peripheral CD4, CD8, CD19 and CD56-positive cell counts 
categorized according to tumoural PD-L1 (Panel G) and PD-L2 expression status 
(Panel H) in HIV-associated NSCLC (n=24). Medians and interquartile ranges are 
reported. Panel I: Volcano plot of differentially-regulated genes identified by Nanostring 
analysis. The Benjamini-Hockberg p-values are correlated to fold-changes in transcripts 
identified in HIV-positive NSCLC (n=5) versus HIV-negative controls (n=3). Transcripts 
achieving statistical significance (FDR q-value of 5%) are highlighted by the presence of 
the corresponding gene name. Panel L. Heat map profile of the 12 transcripts that are 
differentially regulated in HIV-associated NSCLC compared to controls. Expression 
levels are shown as log transformed values of normalized counts (ln2).  
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